Fernando J. Muzzio, PhD, is a Pharmtech editorial advisory board (EAB) member.
Fernando J. Muzzio, PhD
Director, NSF Engineering Research Center on Structured Organic Particulate Systems, Department of
Chemical and Biochemical
Engineering,
Rutgers University
Fernando J. Muzzio is a professor in the Department of Chemical and Biochemical Engineering at Rutgers University. He currently serves as the director of the NSF Engineering Research Center on Structured Organic Particulate Systems, the director of the NSF-NIH Nanopharmaceutical Engineering IGERT training program, the co-chair of the technology subcommittee for the National Institute for Pharmaceutical Technology and Education. He is a member of the editorial boards of Pharmaceutical Technology and the Journal for Pharmaceutical Innovation.
Muzzio has published more than 140 peer-reviewed papers, written eight book chapters, presented numerous papers at major technical meetings, and holds six patents. He has been invited to present at numerous academic, industry, and federal seminars.
He received his PhD from the University of Massachusetts at Amherst in chemical engineering in 1991. His thesis was titled: "Non-Linearity, Chaos, and Self-Similarity: Effects of Mixing, Aggregation, Reaction, and Breakup on Structure Formation." He holds a BS in chemical engineering from the University of Mar del Plata, Argentina.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Adding SYLOID® Mesoporous Silica to Improve Run Time and Yield for Micronization Processes
May 9th 2025A must-read for anyone in the industry looking to enhance their micronization processes. Discover how adding low percentages of SYLOID® mesoporous silica can significantly improve the run time and yield of jet milling processes for hard-to-process Active Pharmaceutical Ingredients (APIs). Imagine achieving a more consistent feed rate and a homogenous final product simply by pre-blending SYLOID® mesoporous silica with your APIs. Grace & Microsize conducted experiments that reveal substantial improvements in both run time and yield, making this paper an essential guide for professionals aiming to optimize their manufacturing processes and boost efficiency and feed rate consistency.